picropodophyllin has been researched along with Rhabdomyosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bujak, J; Kopytko, P; Pawlik, A; Tarnowski, M; Tkacz, M; Zgutka, K | 1 |
| Abraham, J; Hawkins, DS; Keller, C; Malempati, S; McHardy, SF; Michalek, JE; Nelon, LD; Prajapati, SI; Soundararajan, A; Zarzabal, LA | 1 |
2 other study(ies) available for picropodophyllin and Rhabdomyosarcoma
| Article | Year |
|---|---|
Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Ligands; Male; Mice; Podophyllotoxin; Receptor, IGF Type 1; Receptor, Insulin; Rhabdomyosarcoma; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Fluorodeoxyglucose F18; Mice; Podophyllotoxin; Positron-Emission Tomography; Receptor, IGF Type 1; Rhabdomyosarcoma | 2012 |